- A CT-based radiomics nomogram for classification of intraparenchymal hyperdense areas in patients with acute ischemic stroke following mechanical thrombectomy treatment. [Journal Article]
- CONCLUSIONS: The nomogram shows favorable efficacy for differentiating hemorrhage from iodinated contrast extravasation, which might provide an individualized tool for precision therapy.
- PMC Free PDF
- Association between intravenous tirofiban and intracranial hemorrhage in acute large vessel occlusion stroke: insight from the RESCUE BT randomized placebo-controlled trial. [Journal Article]J Neurol. 2023 Jan 25 [Online ahead of print]JN
- CONCLUSIONS: In patients with acute large vessel occlusion stroke, intravenous tirofiban before EVT within 24 h of time from last known well is not associated with increased risk of SICH. Patients who are older, have more severe neurological deficits, or with cardioembolism are at higher risk of SICH with intravenous tirofiban.
- Publisher Full Text (DOI)
- PLATELET SUPPRESSION BY TIROFIBAN AMELIORATES PULMONARY COAGULATION AND FIBRINOLYSIS ABNORMALITIES IN THE LUNGS OF MOUSE ANTIBODY-MEDIATED TRANSFUSION-RELATED ACUTE LUNG INJURY. [Journal Article]Shock. 2023 Jan 16 [Online ahead of print]S
- This study aimed to explore the ameliorating effects of the platelet surface glycoprotein (GP) IIb/IIIa receptor antagonist tirofiban on coagulation and fibrinolytic abnormalities in a mouse model of antibody-mediated transfusion-associated acute lung injury (ALI). This is important since ALI is a major cause of death attributable to the occurrence of adverse transfusion reactions. No information…
- Publisher Full Text (DOI)
- An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives. [Review]High Blood Press Cardiovasc Prev. 2023 Jan 13 [Online ahead of print]HB
- The glycoprotein (GP) IIb/IIIa receptor is found integrin present in platelet aggregations. GP IIb/IIIa antagonists interfere with platelet cross-linking and platelet-derived thrombus formation through the competition with fibrinogen and von Willebrand factor. Currently, three parenteral GP IIb/IIIa competitors (tirofiban, eptifibatide, and abciximab) are approved for clinical use in patients aff…
- Publisher Full Text (DOI)
- Platelet-Mimicking Nanosponges for Functional Reversal of Antiplatelet Agents. [Journal Article]Circ Res. 2023 Jan 10 [Online ahead of print]CircR
- During long-term antiplatelet agents (APAs) administration, patients with thrombotic diseases take a fairly high risk of life-threatening bleeding, especially when in need of urgent surgery. Rapid functional reversal of APAs remains an issue yet to be efficiently resolved by far due to the lack of any specific reversal agent in the clinic, which greatly restricts the use of APAs. Although platele…
- Publisher Full Text (DOI)
- Low-dose intravenous tirofiban infusion after endovascular recanalization for non-acute middle cerebral artery occlusion. [Journal Article]
- CONCLUSIONS: Low-dose intravenous tirofiban infusion (0.2-0.3 mg/h for 48 h) after endovascular treatment seems to be safe and potentially effective for non-acute middle cerebral artery occlusion patients.
- PMC Free PDF
- Factors affecting the outcomes of tirofiban after endovascular treatment in acute ischemic stroke: Experience from a single center. [Journal Article]CNS Neurosci Ther. 2023 Jan 04 [Online ahead of print]CN
- CONCLUSIONS: An effective response to tirofiban is an independent factor in predicting the long-term efficacy outcome, and extending the duration of tirofiban is beneficial for neurological improvement.
- Publisher Full Text (DOI)
- Analysis of risk factors for the efficacy of tirofiban in the treatment of acute ischemic stroke. [Journal Article]Neurol Res. 2023 Jan 04 [Online ahead of print]NR
- CONCLUSIONS: The early curative effect of tirofiban in acute ischemic stroke patients with a heavy drinking history and elevated total cholesterol was poor. In patients with acute ischemic stroke, the higher the NIHSS score was within a certain range (8 < NIHSS ≤15 and the Org 10,172 Trial in the Treatment of Acute Stroke (TOAST) belongs to small-artery occlusion lacunar) at the initiation of treatment and the shorter the time from onset to treatment, the better the early curative effect was.
- Publisher Full Text (DOI)
- Targeting integrin pathways: mechanisms and advances in therapy. [Review]
- Integrins are considered the main cell-adhesion transmembrane receptors that play multifaceted roles as extracellular matrix (ECM)-cytoskeletal linkers and transducers in biochemical and mechanical signals between cells and their environment in a wide range of states in health and diseases. Integrin functions are dependable on a delicate balance between active and inactive status via multiple mec…
- PMC Free PDF
- Tirofiban for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis: A Systematic Review and Meta-Analysis. [Journal Article]Cerebrovasc Dis. 2022 Dec 29 [Online ahead of print]CD
- CONCLUSIONS: Intravenous tirofiban could be safe for patients with AIS undergoing IVT, regardless of receiving EVT. Intravenous tirofiban may reduce mortality rates for patients undergoing bridging therapy. It also could increase the likelihood of a favorable functional outcome, especially for patients receiving IVT only.
- Publisher Full Text (DOI)
- Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018-2021). [Journal Article]Am J Health Syst Pharm. 2022 Dec 26 [Online ahead of print]AJ
- CONCLUSIONS: Rapid changes in anticoagulant and antiplatelet volume at US hospitals during the COVID-19 pandemic highlight the need for institutional protocols to manage fluctuating medication volume demands.
- Publisher Full Text (DOI)
- [Role of platelets aggregation in the process of ductus arteriosus closure of newborn pups]. [Journal Article]Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022 Nov; 34(11):1194-1199.ZW
- CONCLUSIONS: The ductus arteriosus of newborn pups begin to close 1-4 hours after birth, and all closed at 12 hours after birth. The expression of platelet membrane GPIIb-IIIa in ductus arteriosus increase gradually after birth, and the platelet aggregation may participate in and promote ductus arteriosus closure to some extent. Tirofiban, a platelet membrane GPIIb-IIIa receptor antagonist, may delay ductus arteriosus closure of newborn pups to some extent by inhibiting platelet aggregation.
- Publisher Full Text (DOI)
- Endovascular treatment for ischemic stroke patients with and without atrial fibrillation, and the effects of adjunctive pharmacotherapy: a narrative review. [Journal Article]Expert Opin Pharmacother. 2023 Jan 01 [Online ahead of print]EO
- Endovascular thrombectomy (EVT) is associated with good clinical outcomes in patients with ischemic stroke, but the impact of EVT on clinical outcomes in patients with ischemic stroke with and without atrial fibrillation (AF), and the effect of adjunctive pharmacological therapies with EVT, remains unclear.
- Publisher Full Text (DOI)
- Effects of Antecedent Intravenous Thrombolysis on Endovascular Treatment of Acute Stroke Using Tirofiban. [Journal Article]J Vasc Interv Radiol. 2022 Dec 09 [Online ahead of print]JV
- CONCLUSIONS: Tirofiban may be used without increasing the risk of adverse events in selected patients who experienced ischemic stroke and were treated with intravenous thrombolysis and endovascular therapy.
- Publisher Full Text (DOI)
- Effects of Danhong injection combined with tirofiban on cardiac function, myocardial enzyme spectrum and lipoprotein-associated phospholipase A2 level in patients with acute myocardial infarction. [Journal Article]
- CONCLUSIONS: Danhong injection combined with tirofiban can improve the cardiac function, myocardial enzyme spectrum and Lp-PLA2 level in AMI patients.
- PMC Free PDF
- Influence of tirofiban on stroke outcome after mechanical thrombectomy in acute vertebrobasilar artery occlusion. [Journal Article]
- CONCLUSIONS: In AVBAO, tirofiban adjunctive to MT was not associated with an increased risk of sICH. Short-term (in-hospital death, NIHSS at discharge) and long-term outcomes (mRS and death at 3 months) seem not to be influenced by tirofiban use.
- PMC Free PDF
- Effect of Adiponectin on Acute Experimental Cerebral Ischemia/Reperfusion Injury. [Journal Article]Turk Neurosurg. 2022 Aug 09 [Online ahead of print]TN
- CONCLUSIONS: Adiponectin has anti-inflammatory and cerebral protective effects in experimental cerebral I/Rinjury.
- Publisher Full Text (DOI)
- Association of Intravenous Tirofiban with Functional Outcomes in Acute Ischemic Stroke Patients with Acute Basilar Artery Occlusion Receiving Endovascular Thrombectomy. [Journal Article]Cerebrovasc Dis. 2022 Dec 08 [Online ahead of print]CD
- CONCLUSIONS: In patients with acute BAO stroke who underwent endovascular treatment, intravenous tirofiban might be associated with favorable outcome, reduced mortality, and a decreased frequency of ICH.
- Publisher Full Text (DOI)
- Clinical safety and possible efficacy of tirofiban in combination with intravenous thrombolysis by recombinant tissue plasminogen activator for early treatment of capsular warning syndrome (CWS). [Journal Article]
- The purpose of this study was to assess the efficacy and safety of the combination of tirofiban with intravenous thrombolysis (IVT) in treating patients with capsular warning syndrome (CWS) who failed to respond to the treatment of intravenous thrombolysis alone. Tirofiban was approved for the treatment of CWS patients with fluctuating symptoms or no substantial improvement after intravenous thro…
- PMC Free PDF
- The efficacy and safety of intravenous tirofiban in the treatment of acute ischemic stroke patients with early neurological deterioration. [Randomized Controlled Trial]J Clin Pharm Ther. 2022 Dec; 47(12):2350-2359.JC
- CONCLUSIONS: Tirofiban injection exhibited a high safety profile and significantly improved the prognosis of AIS-END patients who missed the intravenous thrombolysis time window.
- Publisher Full Text (DOI)
- Safety and Efficacy of Tirofiban in Severe Ischemic Stroke Patients Undergoing Mechanical Thrombectomy. [Journal Article]
- Tirofiban has recently shown encouraging efficacy and safety among acute ischemic stroke (AIS) patients with mechanical thrombectomy (MT). However, the benefits of tirofiban varied among studies depending on the patient's condition, which was often not well analyzed. This study aimed to identify the characteristics of patients who may obtain the largest benefits from tirofiban. The efficacy endpo…
- PMC Free PDF
- Prolonged Use of Tirofiban Infusion Without Percutaneous Coronary Intervention To Achieve Optimal Results in a COVID-19 Positive Patient With Inferior ST Segment Elevated Myocardial Infarction (STEMI) Secondary to Thromboembolism: A Case Report. [Case Reports]
- Severe acute respiratory syndrome‑coronavirus‑2 (SARS‑CoV‑2), responsible for COVID-19, is mainly a respiratory illness, but it can affect other organs also such as heart, kidneys, and liver. Myocardial injury from COVID-19 has been reported in hospitalized patients ranging from pericarditis and myocarditis to acute coronary syndrome (ACS). COVID-19 is highly hypercoagulable state and is associat…
- PMC Free PDF
- Anti-platelet peptides targeting αIIbβ3 outside-in signaling pathway [Journal Article]Curr Protein Pept Sci. 2022 11 14 [Online ahead of print]CP
- Platelets and their progenitors express high levels of integrin αIIbβ3, which plays a key role in platelet functions, hemostasis, and arterial thrombosis. Because of their quick and high efficacy, the three anti-αIIbβ3 drugs, abciximab, eptifibatide, and tirofiban, are regarded as potent anti-thrombotics and clinically approved by US Food and Drug Administration. However, because they interfere w…
- Publisher Full Text (DOI)
- Safety and efficacy of adjunct tirofiban treatment following mechanical thrombectomy for acute ischemic stroke patients with large vessel occlusion (LVO) resulting in successful reperfusion. [Journal Article]Interv Neuroradiol. 2022 Nov 10 [Online ahead of print]IN
- CONCLUSIONS: Adjunct tirofiban treatment following MT for AIS patients with LVO that resulted in successful reperfusion on DSA was not correlated with the increased risk of safety endpoints on sICH, ICH, and 3-month mortality, and it may be associated with a lower 3-month mRS score.
- Publisher Full Text (DOI)
- Endovascular treatment of challenging aneurysms with FRED Jr flow diverter stents: a single-center experience. [Journal Article]
- CONCLUSIONS: Endovascular treatment of small cerebral aneurysms with FRED Jr is safe and effective even in complex and challenging morphologies allowing high rates of aneurysm occlusion with low periprocedural complications. Our cohort, consisting of a rate 20% acute ruptured aneurysms, is the major additive data to the published literature.
- PMC Free PDF
- Safety Profile and Complication Rates in Emergency Off-label Use of Tirofiban in Interventional Neuroradiology : An Observational Dual Center Study. [Journal Article]
- CONCLUSIONS: Whereas the safety profile of tirofiban when applied off-label in INR is acceptable, the highest risk for relevant tirofiban-associated complications is observed in older patients treated by emergency stenting for acute stroke.
- Publisher Full Text (DOI)
- Prospective pilot study of tirofiban in progressive stroke after intravenous thrombolysis. [Journal Article]
- CONCLUSIONS: Early treatment with low-dose tirofiban in AIS patients with neurologic deterioration after IVT potentially improved functional recovery and attenuated neurologic deficits as early as 7 days and did not increase the risk of various hemorrhagic complications. However, the therapeutic efficacy of tirofiban treatment in END patients needs to be determined by future randomized clinical trials with a large study population.
- PMC Free PDF
- Comparison of predictors of failure of early neurological improvement after successful endovascular treatment for posterior and anterior circulation large vessel occlusion: Data from ANGEL-ACT registry. [Journal Article]Interv Neuroradiol. 2022 Oct 20 [Online ahead of print]IN
- CONCLUSIONS: In selected patients, successful EVT can lead to similar outcomes in PCLVO and ACLVO. Some predictors of fENI in both anterior circulation and posterior circulation were identified in our study, which should be highly considered in the clinical practice in LVO patients undergoing EVT.
- Publisher Full Text (DOI)
- The effects of Anisodamine-Tirofiban Combined Therapy in acute myocardial infarction treated with Percutaneous Coronary Intervention (PCI). [Journal Article]
- CONCLUSIONS: The combined treatment of anisodamine-tirofiban in patients with acute myocardial infarction after percutaneous coronary intervention (PCI) can recover NGF and ESM-1 related proteins, improve postoperative myocardial perfusion, and accelerate the recovery of cardiac function. It is worth promoting in clinic.
- PMC Free PDF